UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): November 2, 2010
PFIZER
INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
1-3619
|
13-5315170
|
(State
or other
|
(Commission
File
|
(I.R.S.
Employer
|
jurisdiction
of
|
(Number)
|
Identification
No.)
|
incorporation)
|
|
|
235
East 42nd Street
|
10017
|
New
York, New York
|
(Zip
Code)
|
(Address
of principal executive offices)
Registrant's
telephone number, including area code:
(212)
733-2323
Not
Applicable
(Former
Name or Former Address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨
Written communication pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2 (b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
Item 2.02
Results of Operations and Financial Condition
On
November 2, 2010, Pfizer Inc. (“Pfizer”) issued a press release announcing its
financial results for the third quarter of 2010. The information contained in
the press release is deemed to be “filed” under the Securities Exchange Act of
1934 as Exhibit 99 to this report, and such press release is incorporated herein
by reference.
Item 9.01
Financial Statements and Exhibits
(d) Exhibits
Exhibit
99 -
|
Press
Release of Pfizer Inc. dated November 2, 2010, reporting Pfizer's
financial results for the third quarter of 2010. Exhibit
99 is deemed to be “filed” under the Securities Exchange Act of 1934 in
this Current Report on Form 8-K.
|
SIGNATURE
Under the
requirements of the Securities Exchange Act of 1934, the registrant has caused
this report to be signed on its behalf by the authorized
undersigned.
|
PFIZER
INC.
|
|
|
|
By:
|
/s/ Matthew Lepore
|
|
|
Matthew
Lepore
|
|
|
Vice
President, Chief Counsel – Corporate Governance,
|
|
|
and
Assistant General Counsel
|
Dated:
November 2, 2010
EXHIBIT
INDEX
Exhibit
No.
|
Description
|
|
|
99
|
Press
Release of Pfizer Inc. dated November 2, 2010, reporting Pfizer's
financial results for the third quarter of
2010.
|